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1. Introduction 
Renal cell carcinomas (RCCs) are the most common epithelial neoplasms of adult kidney. It 
has been estimated that there will be about 60,920 new cases of kidney cancer in the United 
States in 2011 and about 13,120 people will die from this disease (Siegel et al. 2011). 
Currently, surgery remains the only effective treatment for RCC, since metastatic disease is 
highly resistant to radiotherapy and chemotherapy. Approximately 20 to 30% of patients 
with RCCs present with non-resectable metastatic disease and 20 to 40% of patients 
undergoing nephrectomy for clinically localized RCC will develop metastatic disease. In the 
past two decades significant advances in the diagnosis and treatment of patients with RCC 
have resulted in improved survival of a select group of patients. Prior to the availability of 
targeted therapies, Interferon-(IFN) was the standard of care but was associated with a 
low response rate and significant toxicity (Interferon-alpha and survival in metastatic renal 
carcinoma: early results of a randomized controlled trial. Medical Research Council Renal 
Cancer Collaborators 1999). High dose interleukin-2 (IL-2) has a similar response rate as 
IFN, but can cure approximately 3-5% of patients (Yang, Sherry, et al. 2003). Targeted 
molecular therapies include inhibitors of angiogenesis (Yang, Haworth, et al. 2003), 
inhibitors of receptor tyrosine kinases with promiscuous targets including VEGFR1 and 
VEGFR2, PDGFR, C-Kit, Raf kinase, mammalian target of rapamycin (mTOR) (Atkins et al. 
2004; Motzer et al. 2006; Porta et al. 2011) and combination treatment modalities (Escudier et 
al. 2007; Hudes et al. 2007; Motzer et al. 2007). These novel therapies have demonstrated 
improved outcomes and have become the first line of therapy in patients with advanced 
metastatic disease or second line of therapy in patients who have failed prior cytokine 
immunotherapy (Leveridge & Jewett 2011). As new treatment modalities become standard 
of care, clinical practices in diagnosis and treatment of the primary tumor will undergo 
revision. For instance, the role of cytoreductive surgery in patients selected for targeted 
therapy has not yet been established. This could increase the number of cases diagnosed and 
treated based on core needle biopsies alone, presenting new challenges to surgical 
pathologists who will likely have to use smaller amounts of tissue to accurately classify the 
tumor and provide molecular information aimed to personalize clinical care. 
RCC is a heterogeneous neoplasm, which includes distinct histological subtypes (Table 1). 
Among the adult population, clear cell RCC constitutes the most prevalent subtype (70-80%)  
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Histological 
Subtype 
Incidence 5-Year Survival Cell of Origin 
Clear Cell RCC 
 
 
Papillary RCC 
 
 
 
Chromophobe RCC 
 
 
 
Oncocytoma 
70-80% 
 
 
10-15% 
 
 
 
5% 
 
 
 
5% 
45-76% 
 
 
82-90% 
 
 
 
78-92% 
 
 
 
100% 
Proximal 
convoluted tubules 
 
Shared phenotype 
of proximal and 
distal tubules 
 
Intercalated cells of 
collecting tubules 
and ducts 
 
Intercalated cells of 
collecting tubules 
and ducts 
Table 1. Major Histological Subtypes of Renal Cell Neoplasms with Corresponding 
Incidence, Survival, and Cell of Origin 
and has a relatively unfavorable prognosis (Amin et al. 2002; Eble et al. 2004). Papillary and 
chromophobe RCCs are less common, comprising 10-15% and 5%, respectively, and have a 
better prognosis compared to clear cell RCC (Amin et al. 2002). Oncocytoma is a benign renal 
cell tumor characterized by an extremely favorable prognosis. Renal epithelial tumors are 
thought to originate in cells of different compartments along the nephron. Clear cell RCC is 
believed to arise from the proximal tubules. Tumors that originate in the collecting tubules and 
ducts include chromophobe RCC, oncocytomas, and the more rare collecting duct and 
medullary carcinomas. The histogenesis of papillary carcinoma is controversial with some 
studies suggesting a proximal tubule origin while phenotyping by immunohistochemistry 
supports a distal nephron origin. Renal tumors with papillary growth include papillary RCC 
types 1 and 2, clear cell RCC with papillary features and the recently described clear cell 
papillary RCC (CPRCC) (Gobbo et al. 2008). CPRCC is a subtype of renal cell carcinoma 
characterized by cells with clear cytoplasm arranged in papillary structures which was first 
described in patients with end stage renal disease, but later also identified in kidneys 
unaffected by end stage renal disease (Fuzesi et al. 1999; Gobbo et al. 2008).  
Immunohistochemistry is useful in distinguishing the different subtypes of renal neoplasms. 
Clear cell RCCs are frequently CD10 positive but AMACR and CK7 negative; papillary 
carcinoma, on the other hand, is positive for CK7 and AMACR and usually negative for 
CD10. Recent studies in CPRCC demonstrate positive immunoreactivity for CK7 but 
negative AMACR and CD10. These and other immunohistochemical markers are currently 
used routinely in diagnostic histopathology to help classify tumors. However, this is a 
constantly evolving field and new immunohistochemical and molecular markers are being 
investigated to address new clinical needs.  
Steroid receptors are a family of ligand dependent transcription factors, which have 
important roles in control of growth and differentiation in many non-neoplastic and 
neoplastic cell types. The steroid receptor family is characterized by a unique modular 
structure, with receptors classically divided into three main domains and several  
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Steroid 
Receptor 
Expression in 
Normal Kidney 
Tumor Type Clinical 
Relevance 
References 
 
GR 
 
 
 
 
MR 
 
 
 
 
ER 
 
 
 
 
 
PR 
 
 
 
 
 
 
 
 
AR 
 
 
 
 
VDR 
 
 
 
 
 
RAR and 
RXR 
 
 
 
Proximal tubules, 
glomeruli 
 
 
 
Distal tubules, 
loops of Henle 
and collecting 
ducts 
 
Interstitial 
stromal cells 
 
 
 
 
Interstitial 
stromal cells 
 
 
 
 
 
 
 
Proximal and 
distal tubules 
 
 
 
Distal tubules 
and collecting 
ducts 
 
 
 
Proximal tubules, 
interstitial cells 
 
Clear cell RCC 
 
 
 
 
Oncocytoma and 
chromophobe RCC 
 
 
 
Cystic nephroma, 
mixed epithelial 
and stromal tumor, 
angiomyolipoma 
with epithelial cysts 
 
Cystic nephroma, 
mixed epithelial 
and stromal tumor, 
angiomyolipoma 
with epithelial 
cysts, chromophobe 
RCC and 
oncocytoma 
 
Clear cell, papillary, 
and chromophobe 
RCC 
 
 
Papillary RCC, 
chromophobe RCC, 
oncocytoma, 
collecting duct 
carcinoma 
 
Clear cell RCC, 
chromophobe RCC 
(RAR-) 
 
Increased 
expression is a 
favorable 
marker 
 
Diagnostic 
marker 
 
 
 
Hormonal 
mechanism of 
pathogenesis 
 
 
 
Hormonal 
mechanism of 
pathogenesis 
Diagnostic 
marker 
 
 
 
 
Increased 
expression is a 
favorable 
marker 
 
Diagnostic 
marker 
 
 
 
 
Increased 
expression of 
RXR- is a 
favorable 
marker 
 
Yakirevich et al. 
2011 
 
 
 
Yakirevich et al. 
2008 
 
 
 
Adsay et al. 2000 
 
 
 
 
 
Adsay et al. 2000 
Tickoo et al. 
2008 
Mai et al. 2008 
 
 
 
 
 
Kimura et al 
1993 
Langner et al, 
2004 
 
Obara, Konda et 
al. 2007 
Liu et al. 2006 
 
 
 
Goelden et al. 
2005 
Obara, Konda et 
al. 2007 
 
Table 2. Steroid Receptors in Renal Cell Neoplasms 
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subdomains or regions. In general, the receptor members share a variable amino-terminal 
transactivation domain, a central and well-conserved DNA-binding domain (DBD), and a 
moderately conserved carboxy-terminal domain responsible for ligand binding. The latter 
domain also contains activating functions. The well known members of the steroid receptor 
family includes glucocorticoid (GR), mineralocorticoid (MR), progesterone (PR), androgen 
(AR), estrogen (ER), vitamin D (VDR), thyroid, and retinoic acid (RAR)/retinoid X receptors 
(RXR) (Fuller 1991).  
There is emerging evidence that steroid receptors can induce gene expression through both 
ligand-dependent and ligand-independent pathways, and distinct families of genes are 
likely to be regulated depending on the mechanism of nuclear receptor signaling. Until 
recently, the study of steroid receptors in renal cell neoplasm’s (RCNs) has been limited to 
ER and PR. The employment of novel techniques for studying steroid receptors in RCCs, 
such as immunohistochemistry, tissue microarray technology, and quantitative real-time 
PCR has revealed the presence and biologic importance of several steroid receptors in 
RCNs, including GR, MR, VDR, and others (Table 2). This review will focus on histogenetic, 
diagnostic, and prognostic implications of steroid receptor expression in RCNs. 
2. Glucocorticoid receptor  
Glucocorticoids mediate their effects via their intracellular glucocorticoid receptors. Studies 
of GRs have revealed that there is only one GR gene, but several GR receptor isoforms 
resulting from alternative splicing or alternative translation initiation (Pujols et al. 2002; 
Revollo & Cidlowski 2009). Two main human isoforms, GR- and GR-, have a different 
distribution pattern and biologic activity in healthy and diseased human cells and tissues. It 
has been demonstrated that GR- is the predominant isoform expressed in a large number 
of healthy human tissues including brain, liver, kidney, skeletal muscle, lung, and other 
organs. The GR- isoform possesses steroid binding activity. In contrast, GR- expression 
level is lower than that of the GR- isoform and is relatively abundant in inflammatory 
blood cells (Pujols et al. 2002). In non-activated cells, the GR resides in the cytoplasm as a 
part of a large complex consisting of chaperone and cochaperone proteins including heat 
shock proteins hsp90, hsp70, immunophilins FKBP51 and FKBP52, and others (De Bosscher 
et al. 2003). Upon ligand binding, GR undergoes phosphorylation and activation and 
translocates from the cytoplasm to the nucleus where it converts to a DNA-binding form. 
Transcriptional responses triggered by activated GR include both positive and negative 
gene regulation. The direct positive transcriptional regulation of genes (transactivation) 
requires binding of the GR homodimer to glucocorticoid-response elements (GRE) in gene 
promoters. The indirect negative regulation (transrepression) is mediated through negative 
cross-talk with other transcription factors including AP-1, NF-kB and p53 (Beato et al. 1995). 
As a result, glucocorticoids modulate a variety of physiologic and pathologic processes, 
including among others cellular differentiation, growth, inflammation, immune response, 
and carbohydrate metabolism. 
2.1 Expression of GR in the normal kidney 
In normal human kidneys GRs contribute to the regulation of renal fluid and electrolyte 
homeostasis. Keeping with their physiologic function, GRs are differentially distributed 
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along the kidney nephron. In vitro studies have implicated GRs in the regulation of 
ammoniagenesis, gluconeogenesis, GFR, Na-H exchange and Na-phosphate co-transport, all 
of which are proximal renal tubule processes (Baylis et al. 1990; Boross et al. 1986; Campen 
et al. 1983; Freiberg et al. 1982). Measurement of GRs in normal rat kidney cortical tubules 
enriched in proximal tubules yielded three to six fold higher GR content as compared to the 
distal tubules (Mishina et al. 1981). Predominant proximal tubule localization of GR was 
demonstrated by quantitation of GR mRNA levels in microdissected nephron segments 
from the rat kidney by a competitive polymerase chain reaction (PCR) technique (Todd-
Turla et al. 1993). GR mRNA was twofold more abundant in glomeruli, proximal tubule, 
and thick ascending limb segments than in the collecting duct segments (Todd-Turla et al. 
1993). In an additional study GR mRNA was localized by in-situ hybridization 
predominantly to renal proximal tubules and cortical collecting tubules with lower levels in 
distal collecting tubules of the rat kidney (Roland et al. 1995). In a recent study we provided 
immunohistochemical evidence of GR expression in the proximal tubular epithelium of 
normal human kidneys and in the epithelial cells of normal renal glomeruli (Yakirevich et 
al. 2011). However, several in vitro and in vivo studies have demonstrated that 
glucocorticoids can exert mineralocorticoid-like effects, such as Na+ reabsorption and K+ 
secretion, in the distal nephron (Morris & Souness 1992; Naray-Fejes-Toth & Fejes-Toth 1990; 
Thomas et al. 2006).  
2.2 Expression of GR in kidney tumors 
Initial studies of GR expression in RCCs based on ligand-binding assays in the early 1980’s 
demonstrated the presence of GRs in kidney tumors (Bojar et al. 1979; Chen et al. 1980; 
Hemstreet et al. 1980; Liu et al. 1980). In these pioneer studies renal tumors were not 
subdivided into different histologic subtypes and were all designated as RCCs. Bojar et al. 
demonstrated GRs in 10 of 15 tumors studied (Bojar et al. 1979). The average dexamethasone 
binding capacity was calculated and found to be 7.1 fmol/mg of cytosol protein. The ligand 
specificity experiments clearly indicated that binding to GRs is not restricted to 
glucocorticoids alone. Progesterone and aldosterone turned out to be moderate competitors 
for dexamethasone binding. Medroxyprogesterone acetate, the compound widely used in 
hormone therapy of advanced renal cancer in man, was demonstrated to be one of the 
strongest inhibitors of [3H] dexamethasone. The binding of medroxyprogesterone acetate to 
GRs may represent the primary mechanism of action of the compound in causing tumor 
regression. Hemstreet et al. identified and measured the levels of GRs in 47 autologous pairs 
of normal and neoplastic renal tissue (Hemstreet et al. 1980). Glucocorticoid receptors were 
demonstrated in this study in normal and neoplastic tissues of both sexes. The levels of GRs 
were higher in the tumors (mean 31.3 fmol/mg) than in the normal tissue (18.5 fmol/mg). In 
an additional study conducted at the same time, Liu et al. reported high concentrations of 
GRs in four of seven RCC cases (Liu et al. 1980). The levels of GRs in RCCs were comparable 
to those in the glucocorticoid-responsive rat liver. Furthermore, the GR levels in RCCs were 
comparable to human acute lymphocytic leukemia cells sensitive (0.03 pmol/mg cytosol 
protein), in contrast to those that have become resistant (0.015 pmol/mg cytosol protein) to 
glucocorticoids. Chen et al. detected GRs in cytosol of RCCs (Chen et al. 1980). Competition 
experiments demonstrated that progestin competed for the GR sites in all renal tumors 
tested, whereas diethylstilbestrol and testosterone were weak or not competitive. 
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Development of antibodies against human GR enabled immunohistochemical and Western 
blot assessment of GR protein expression. In addition, molecular studies utilizing reverse 
transcriptase polymerase chain reaction (RT-PCR) revealed that most commonly used RCC 
cell lines express high levels of GR. In a study by Arai et al., two RCC cell lines OUR-10 and 
NC65 expressed high levels of GR, whereas Caki-1 cell exhibited low levels of GR 
expression by Western blot (Arai et al. 2008). Iwai et al. demonstrated GR mRNA expression 
in the A498, RCC270, Caki1, and ACHN renal carcinoma cells. A498 and RCC270 expressed 
especially high levels of the GR gene (Iwai et al. 2004). Recently, using tissue microarray 
technology and real-time RT-PCR we described the immunohistochemical and mRNA 
expression of GRs in different histologic subtypes of RCNs including clear cell RCC, 
papillary RCC, chromophobe RCC, and oncocytoma (Yakirevich et al. 2011). We found that 
GRs are strongly expressed in the majority of clear cell RCCs (66%), in 26% of papillary 
RCCs, and in only 6% of chromophobe RCC and 14% of oncocytomas. Within the clear cell 
carcinoma group, most positive cases (87%) demonstrated strong expression, whereas only 1 
papillary RCC, 1 chromophobe RCC and none of the oncocytomas demonstrated strong 
immunoreactivity. In this study we used commercially available rabbit-antihuman GR 
polyclonal antibody PA1-511A from Affinity Bioreagents (Golden, CO) which recognizes 
both the - and - isoforms of GR. In order to recognize specific isoform expressed in RCC, 
we measured both isoforms by quantitative real-time PCR and demonstrated that RCCs 
express GR- isoform. We found that GR expression is associated with tumors of low 
nuclear grade (Fuhrman grade 1 and 2) and low stage (stage 1 and 2). Although GR 
expression was demonstrated predominantly in clear cell RCC group, the loss of GR 
expression in high-grade tumors and overlap with other histologic subtypes of RCCs limit 
the diagnostic utility of this marker. GR appears to be a marker of less aggressive behavior 
in RCC as there is significant correlation between GR expression and overall survival in 
RCC. By the end of follow-up 86% of CRCC patients with tumors expressing GRs were alive 
as compared to 54% of patients whose tumors were negative. 
Since GRs are cytoplasmic receptors, which are translocated to the nuclei upon activation, 
the predominantly nuclear immunoreactivity of GRs suggests that these receptors are 
activated in RCCs. Association of GR expression with less aggressive behavior also suggests 
the tumor-suppressive role of GRs. Signaling through GRs in renal cancer cells involves 
suppression of other transcription factors, including nuclear factor kB, AP-1, CREB, CCAAT 
enhancer binding protein (C/EBP), signal transduction activator of transcription (STAT), 
p53, Smad, etc (De Bosscher et al. 2003). Treatment of RCC cell lines with glucocorticoids 
(dexamethasone) inhibits the activation of nuclear factor kB and its downstream products 
including IL-2, IL-6, IL-8, and vascular endothelial growth factor which have been 
demonstrated to promote growth of RCC cell lines (Arai et al. 2008; Iwai et al. 2004; Miki et 
al. 1989; Takenawa et al. 1995). Glucocorticoids have long been used as anti-inflammatory 
drugs, and have been beneficial in the treatment of hematopoietic neoplasms (multiple 
myeloma) and solid malignancies such as hormone-refractory prostate cancer (Greenstein et 
al. 2002; Storlie et al. 1995). Although glucocorticoids have not been implicated in the 
treatment of patients with renal cancer, there are few case reports describing the beneficial 
effects of incidental glucocorticoid treatment in metastatic RCC (Christophersen et al. 2006; 
Omland & Fossa 1989; Tanaka et al. 2003). Palliation treatment with oral dexamethasone 
was associated with complete regression of pulmonary and brain metastases (Omland & 
Fossa 1989). In another case, multiple lung and bone metastases of RCC completely 
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regressed after palliative treatment with betamethasone (Tanaka et al. 2003). A 10 year 
complete remission of metastatic RCC to the liver and retroperitoneal lymph nodes was 
described in a patient who received palliative cortisone therapy (Christophersen et al. 2006). 
The mechanism of metastases regression in these cases is unknown and is not likely to be 
immune related, because glucocorticoids are known to suppress the immune system. These 
observations suggest that GR and its agonists may have a potential role in novel anti-cancer 
hormonal therapies in clear cell RCC. 
3. Mineralocorticoid receptor 
The mineralocorticoid receptor (MR) has long been considered as a secondary 
glucocorticoid receptor, even though specific roles of its natural ligand, aldosterone, have 
been well established since the purification of electrocortin more than 50 years ago. 
Aldosterone was initially restricted to the control of sodium reabsorption in the kidney, 
thereby being recognized as a major regulator of volume status and blood pressure. The 
cloning of a specific receptor for aldosterone (Arriza et al. 1987) definitively moved MR out 
of the shadow of GR and opened a new era of exciting biological, biochemical, and genetic 
studies that have provided important insights into the complexity of MR action. The MR  is 
closely related to GR and is 94% homologous in the DNA binding domain and 57% 
homologous in the ligand binding domain, but only 15% homologous in the N-terminal 
region (Evans 1988). The MR has a similar affinity for the mineralocorticoid aldosterone and 
the glucocorticoids corticosterone and cortisol (Krozowski & Funder 1983). Although rats 
and mice synthesize only corticosterone, cortisol is the predominant glucocorticoid in 
humans and many other mammals, including rodents. Since the circulating levels of 
glucocorticoids are several orders of magnitude higher than those of aldosterone, the 
primary mineralocorticoid, glucocorticoid activation of MR may be functionally significant. 
Specificity is conferred by the enzyme 11-hydroxysteroid dehydrogenase type II (11-
HSD2) which converts the cortisol to the less active compound cortisone, thus allowing 
aldosterone binding to MR. In the absence of ligand, MRs are located in both the cytosol and 
nucleus bound by a variety of chaperone proteins, including hsp90. Upon exposure to either 
aldosterone or corticosterone, most MRs are found in the nucleus, where they bind to 
hormone-response elements and mediate gene expression of signaling proteins regulating 
water and electrolyte transport including K-ras, serine-threonine kinase Sgk1, and 
corticosteroid hormone-induced factor (Connell & Davies 2005). The most recent role of 
aldosterone in renal and cardiac fibrosis has indicated a pro-fibrotic role for MR and the 
product of 11-HSD2, cortisone or 11-dehydro-corticosterone in the regulation of this 
process (Brem et al.).  
3.1 Expression of MR in the normal kidney  
In contrast to GRs which are expressed in a broad variety of cells, expression of MRs is 
restricted to fewer cell types. The MR is expressed in so-called “classical” aldosterone target 
tissues, which are sodium-transporting epithelia (kidney, colon, pancreas, salivary, and 
sweat glands) and in a variety of non-epithelial target tissues such as the central nervous 
system, mononuclear lymphocytes, large blood vessels, and the heart (Arriza et al. 1987; 
Sasano et al. 1992). A general agreement exists that the distal nephron is an aldosterone-
specific target site. Specific nuclear binding sites for aldosterone exist from the thick 
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ascending limb of Henle’s loop (cortical part) to the distal collecting duct in rabbit and rat 
kidneys (Farman & Bonvalet 1983; Farman et al. 1982). MR is expressed in the distal tubules, 
the connecting tubules, and along the collecting ducts at the mRNA level in rat and rabbit 
kidneys (Escoubet et al. 1996; Todd-Turla et al. 1993) and at the protein level in rabbit 
kidneys (Lombes et al. 1990). Immunohistochemical studies showed that in normal human 
kidney MR is expressed in the distal convoluted tubules, collecting ducts, and loops of 
Henle with predominant nuclear localization (Hirasawa et al. 1997; Sasano et al. 1992; 
Yakirevich et al. 2008). 
3.2 Expression of MR in kidney tumors 
More than 30 years ago Rafestin-Oblin et al. demonstrated the presence of high-affinity sites 
for aldosterone in normal human kidneys using a ligand-binding assay. In RCCs the cytosol 
and nuclear aldosterone binding was significantly lower than in normal tissues (Rafestin-
Oblin et al. 1979). However, this study focused exclusively on clear cell RCCs. Recently 
using immunohistochemistry we analyzed tissue microarray specimens from patients with 
different histologic subtypes of renal cell neoplasms, and in addition, we quantitated MR 
mRNA by real time RT-PCR (Yakirevich et al. 2008). Most of the chromophobe RCC (90%) 
and oncocytomas (93%) strongly expressed MR. No MR immunoreactivity was detected in 
clear cell RCC, including clear cell carcinoma with predominantly granular cytoplasm, or in 
papillary RCC. The MR+ immunophenotype of chromophobe carcinoma and oncocytoma 
reflects their histogenetic origin from phenotypically similar distal convoluted tubules and 
collecting ducts, whereas absence of immunoreactivity in clear cell RCC is consistent with its 
origin from proximal convoluted tubules. As we described in the previous section, proximal 
tubules and histogenetically related clear cell RCCs express high levels of GR. MR appears 
to be a sensitive and specific marker of the distal nephron and its related neoplasms 
(chromophobe RCC and oncocytoma) and may be considered in the immunohistochemical 
panel to more accurately subtype renal cell tumors. 
4. Estrogen receptor 
The effects of estrogens are mediated by estrogen receptors (ERs). ERs were discovered in 
the 1960’s by Jensen and Jacobson (Jensen et al. 2010). The basic structure of ER protein is 
similar to other steroid receptors and contains a DNA binding domain, transcription 
modulating domain, and steroid hormone binding domain. There are two ER types encoded 
on different chromosomes: ER- cloned in 1986 and ER-, which was discovered in 1996 
(Greene et al. 1986; Kuiper et al. 1996). ER- is expressed in a variety of human organs, 
mainly reproductive, including the mammary gland, ovary, uterus, and vagina (Muramatsu 
& Inoue 2000). ER- is expressed in genitourinary human tissues such as prostate, ovary, 
testis, bladder, uterus, and renal pelvis, in the central nervous system, and is especially 
increased compared to ER- in various fetal tissues such as adrenals (Gustafsson 1999). The 
affinity of ER- to bind estradiol-17 is similar to the ER- form. However, ER- binds both 
androgens and phytoestrogens with greater affinity. The main physiologic role of ERs is 
implicated in the control of proliferation, differentiation, and development of many tissues. 
In contrast to the beneficial physiologic effects, ERs may also promote the development and 
growth of variety of cancers, including breast, endometrial and ovarian carcinomas in 
humans (Speirs et al. 1999) and renal tumors in Syrian hamsters (Li et al. 2001). 
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4.1 Expression of ER in the normal kidney 
Expression of ERs was extensively studied in hamster kidneys; however, the distribution of 
ER in normal hamster kidney is controversial. In a study by Bhat et al. who treated hamsters 
with estradiol to induce tumors, ER immunolocalization in normal kidneys of estrogen-
treated hamsters or in untreated controls was identified only in the renal glomerular 
pododcytes, mesangial and parietal cells and in several interstitial cell types but not in the 
tubular epithelia of the cortex (Bhat et al. 1993). In addition, arterial cells, including pericytes 
and endothelial cells of the arteriolae rectae and endothelial cells of the arterial vasa recta, 
strongly expressed ER. The receptor distribution in kidneys of untreated female hamsters 
matched that of males, but the intensity of staining was higher than in male kidneys. 
Another study confirmed immunohistochemical expression of ER in interstitial cells and 
localized these cells to the corticomedullary junction (Li et al. 2001). The authors found that 
estrogen treatment causes a significant increase in ER- positive interstitial cells compared 
to untreated controls and hypothesized that renal tumors arise from a subset of 
multipotential interstitial cells driven to proliferate by estrogens. However, in contrast to the 
study by Bhat et al., in this study ER expression was consistently demonstrated in nuclei of 
proximal tubules and disappeared after estrogen treatment.  
4.2 Expression of ER in kidney tumors 
Initial biochemical studies of ER status in renal tumors were performed in early 1980s by the 
dextran-coated charcoal method and the sucrose gradient centrifugation assay. These 
biochemical assays were based on cytosol preparations containing high, but unknown levels 
of plasma contamination. Furthermore, there was significant inconsistency in the number of 
tumor cells present within the specimens (Karr et al. 1983). Therefore, the level and 
frequency of ER expression in human kidney tumors were highly variable. Hemstreet et al. 
reported detectable ERs in 30% of the tumors compared to 40% of normals, whereas in other 
studies utilizing similar biochemical techniques ERs were not detected or detected in a 
rather low percentage of 4-9% of tumors (Hemstreet et al. 1980; Karr et al. 1983; Pearson et 
al. 1981). In a more recent immunohistochemical analysis of steroid hormone expression in 
tissue microarrays containing 182 RCCs of different histologic subtypes, Langer et al. 
demonstrated ER immunoreactivity in less than 10% of tumor cells in only 2 of 182 of 
patients  (1.1%), including one clear cell RCC and one chromophobe RCC (Langner et al. 
2004). Thus, the biochemical and immunohistochemical results provide evidence that ER is 
not expressed or very rare expressed in low levels in RCCs.  
Recently, several benign renal tumors, characterized by the presence of stroma that 
resembles ovarian, endometrial, and mullerian-like, have been described, including cystic 
nephroma, mixed epithelial and stromal tumor (MEST) and angiomyolipomas with 
epithelial cysts (AMLEC) (Fine et al. 2006; Turbiner et al. 2007). Adsay et al. detected ERs in 
nuclei of the spindle cells in seven of 12 MESTs (Adsay et al. 2000). The staining was strong 
and diffuse and was present predominantly in the areas with long, slender, fibrocyte-like 
cells. In three of these cases, the epithelial cells also exhibited a cytoplasmic reaction with 
antibody to ER. Distinctive clinical and pathologic features characterize these lesions. Most 
of the patients in study of Adsay et al. were middle-aged (perimenopausal) females (mean 
age, 56 years) who had a long-term history of estrogen use. The only male patient also had a 
history of diethylstilbestrol exposure for 7 years followed by 4 years of lupron therapy for 
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prostatic adenocarcinoma. These clinical findings, combined with frequent ER expression 
detected by immunohistochemistry raise the possibility of hormonal mechanism of 
pathogenesis of these tumors. It is plausible that the spindle cells of these tumors arise from 
a “periductal fetal mesenchyma” present in epithelial structures of organs such as kidney, 
pancreas, and liver. The primitive mesenchyme may have the capacity to interact with 
epithelia. Alterations of hormonal milieu (perimenopausal changes or therapeutic hormones 
with unopposed estrogens) may induce proliferation of this mesenchyme, which in turn 
activates the growth of epithelial component. 
5. Progesterone receptor 
The progesterone receptor (PR) has two predominant isoforms: PR-, and PR-, which are 
produced from a single gene by alternative promoter usage (Jeltsch et al. 1986). These 
isoforms have similar steroid hormone and DNA binding activities, but PR- has a much 
higher transcriptional activating potential. Clinically, PR expression is routinely assessed by 
immunohistochemistry using an antibody that recognizes both PR- and PR-. 
5.1 Expression of PR in the normal kidney 
No detectable PR staining was seen in renal sections from untreated castrated male hamsters 
in a study by Bhat et al. (Bhat et al. 1993). However, after estrogen treatment, PR expression 
was detected in single interstitial cells. The pattern of PR immunoreactivity was largely 
confined to interstitial cells located at the renal corticomedullary region, similar to ER 
expressing cells described above. PRs were identified in normal human kidneys by 
biochemical and more recently immunohistochemical techniques (Hemstreet et al. 1980; 
McDonald et al. 1983). Interesting, in normal human kidneys PRs were detected by 
immunohistochemistry in interstitial stromal cells, some tubules, and mesangial cells of 
glomeruli in two of seven cases (Tickoo et al. 2008). 
5.2 Expression of PR in kidney tumors 
Expression of PR in kidney tumors was studied in parallel with ER analysis. The level and 
frequency of PR in human kidney tumors is highly variable when analyzed biochemically 
varying from 0 to 23% (Hemstreet et al. 1980; Karr et al. 1983; Pearson et al. 1981). 
Immunohistochemical analysis of steroid hormone expression in tissue microarrays 
containing 182 RCCs of different histologic subtypes demonstrated PR immunoreactivity in 
less than 10% of tumor cells in only two of 182 patients, including one clear cell RCC and 
one papillary RCC (Langner et al. 2004). PRs were found in stromal cells of renal neoplasms 
with ovarian-like stroma, although less frequently as compared to ER (Adsay et al. 2000). 
More recently Mai et al. identified PR immunoreactivity of tumor cells and stromal cells 
within the neoplasm and/or surrounding capsule in renal oncocytoma and chromophobe 
RCC (Mai et al. 2008). This immunoreactivity was not seen in other tumors with 
oncocytic/eosinophilic cytoplasm, such as papillary RCC with eosinophilc cytoplasm or 
clear cell RCC with eosinophilic cytoplasm. PR appears to be a sensitive and highly specific 
marker for renal oncocytoma and a highly specific marker for chromophobe RCC. It was 
demonstrated that PR immunoreactivity is more extensive in oncocytoma than in 
chromophobe RCC, therefore, the extent of PR immunoreactivity could be useful in 
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distinguishing oncocytoma from chromophobe RCC. The presence of PR in oncocytoma and 
chromophobe RCC provides additional support to the histopathogenetic relationship 
between renal oncocytoma and chromophobe RCC. 
6. Androgen receptor 
Androgens are essential for differentiation and growth of male reproductive organs and for 
various biological effects in the kidney, brain, liver, muscle, bone and skin. Androgens 
include testosterone and dihydrotestosterone and mediate their biologic effect through the 
androgen receptor (AR). The AR gene is located on chromosome Xq11-12 (Brown et al. 1989; 
Lubahn et al. 1988). Males have a single copy of the gene allowing phenotypic manifestation 
of any genetic alteration. Transcription of the AR gene is cell-specific and modified by age, 
androgen and other steroid hormones (Gelmann 2002). Androgen is best known to influence 
development and growth of prostate cancer. However, its metabolic role in cancer is not 
limited to the prostate and a number of studies utilizing animal models combined with 
clinical and epidemiologic data suggest a role for androgen in RCC (Concolino, Marocchi, 
Conti et al. 1978; Karr et al. 1983).  
6.1 Expression of AR in the normal kidney 
AR is ubiquitously expressed in the whole body with studies showing detectable levels of 
protein and mRNA in adrenal glands, uterus, aorta, adipose tissue, kidney, spleen, heart, 
lung, large intestine, stomach, small intestine and liver (Kimura et al. 1993; Ruizeveld de 
Winter et al. 1991; Takeda et al. 1990). In normal kidneys AR expression was consistently 
demonstrated to be present in the nuclei of distal tubule cells (Kimura et al. 1993; Li et al. 
2010). Additionally, a study by Takeda et al. showed AR immunoreactivity not only in the 
distal tubule but also in the proximal tubule and focal parietal expression in the Bowman’s 
capsule (Takeda et al. 1990).  
6.2 Expression of AR in kidney tumors 
The hormone dependence of RCC has been established in animal models and in humans for 
many years (Bloom 1973; Concolino, Marocchi, Conti et al. 1978; Concolino, Marocchi, 
Tenaglia et al. 1978; Li et al. 1977). In humans, extensive research on AR in RCC has shown 
variable results (Concolino et al. 1981; Jakse & Muller-Holzner 1988; Karr et al. 1983; Klotzl 
et al. 1987; Nakano et al. 1984; Noronha & Rao 1985) In a case series study by Brown et al., 
that included 12 primary clear cell RCCs and 5 clear cell RCCs metastatic to the central 
nervous system, AR immunoreactivity was present in five primary and one metastatic RCC 
(Brown et al. 1998). A more recent study by Langner et al. demonstrated that AR 
immunoreactivity was not detectable in non-tumoral kidney tissue (Langner et al. 2004). 
However, AR was found in 15% of patients with RCC and inversely correlated with 
histopathologic stage, with 27% of pT1 tumors being positive versus 4% of pT3 tumors. 
Furthermore, expression of AR was higher in pT1a tumors compared to pT1b (32% vs. 17%). 
Additionally, AR expression inversely correlated with nuclear grade with 21% positivity in 
nuclear grades 1 and 2 and 7% in nuclear grades 3 and 4. Univariate analysis showed a 
longer disease free survival in patients with AR positive tumors compared to patients with 
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AR negative tumors (Langner et al. 2004). These results reflect similar trends observed with 
GRs in RCC (Yakirevich et al. 2011), however, the diagnostic, prognostic or therapeutic 
utility of AR analysis in RCC is uncertain and might require further investigations. 
7. Vitamin D receptor 
Vitamin D is a lipid-soluble compound whose major function is the maintenance of 
adequate plasma levels of calcium and phosphorus, important for bone mineralization, 
neuromuscular transmission and general cellular metabolism. Vitamin D receptor (VDR) is 
present in various tissues that do not participate in calcium metabolism and regulates the 
expression of hundreds of genes that control cell proliferation, differentiation and 
angiogenesis. Low levels of vitamin D have been associated with increased incidence of 
colon, prostate and breast cancer (Thacher & Clarke 2011). Recent studies suggest that 
vitamin D may be inversely associated with the risk of RCC. (Bosetti et al. 2007; Ikuyama et 
al. 2002; Karami et al. 2008; Obara, Suzuki et al. 2007). Vitamin D receptor is expressed in 
malignant tumors, including RCC, and mediates the biological actions of 1,25(OH)2D3 
(Lamprecht & Lipkin 2003). In this section, we will review the current literature on the 
relevance of vitamin D and its receptor in RCC.  
7.1 Expression of VDR in the normal kidney 
The kidney is a major organ for vitamin D metabolism and calcium homeostasis. Activation 
of vitamin D involves conversion of 7-dehydrocholesterol to cholecalciferol by UVB 
radiation in the skin. Cholecalciferol is metabolized by the 25-hydroxylases (CYP2R1 and 
CYP27A1) in the liver to 25-hydroxycholecalciferol (25(OH)D3). 25(OH)D3  then undergoes 
glomerular filtration and is subsequently converted to the active form calcitriol 
(1,25(OH)2D3) by the 1-hydroxylase (CYP27B1) located primarily in the proximal tubule. 
Calcitriol binds to an intracellular receptor (VDR), a ligand dependent transcription factor 
belonging to the class II nuclear receptor subfamily. The effect of calcitriol is negatively 
controlled by CYP24A1 (Fleet 2008; Nykjaer et al. 1999). Immunohistochemistry studies of 
non-tumoral kidney show expression of VDR predominantly in the distal tubules and 
collecting ducts with only faint or lack of stain in the proximal tubule cells (Blomberg Jensen 
et al. 2010; Liu et al. 2006; Obara, Konda et al. 2007). This expression pattern is consistent 
with studies that demonstrate that vitamin-D induced calcium re-absorption occurs in the 
distal tubules (Li & Christakos 1991). 
7.2 Expression of VDR in kidney tumors 
In keeping with absence of VDR expression in the proximal tubule, a study by Liu et al. 
showed that clear cell RCC is generally negative for VDR by immunohistochemistry and 
showed decreased mRNA level compared to non-tumoral kidney control tissue by RT-PCR 
(Liu et al. 2006). When whole sections of tumors were stained, expression of VDR was 
present only focally in the peripheral region of the tumor. Previously, a study by Madej et 
al. showed that expression of VDR in clear cell RCC was similar to control tissue by Western 
and Northern blot analysis (Madej et al. 2003). This discrepancy could be due to a difference 
in the degree of differentiation of the tumors analyzed in each study. While the expression 
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level seems not to be affected by the Fuhrman nuclear grade, increased VDR 
immunoreactivity was observed in sarcomatous and poorly differentiated areas of RCC and 
in metastatic tumors or in intravascular tumor islands (Liu et al. 2006).  
A different study by Blomberg Jensen et al. showed that VDR mRNA was detected in all 
normal kidney samples while almost undetectable in clear cell RCC with similar results 
confirmed by Western blot (Blomberg Jensen et al. 2010). Additionally, in this study, the 
authors investigated the expression of Vitamin D activating enzymes including CYP2R1, 
CYP27A1, and CYP27B1. The 1 -hydroxylase (CYP27B1) was present in all normal samples 
with varying degrees of expression levels, the lowest expression in atrophic kidneys. By 
immunohistochemistry and in-situ hybridization, expression of CYP2R1 and CYP27A1 was 
localized to the distal tubule, collecting ducts and minimal expression in the proximal 
tubule. Expression of CYP27B1 was more prominent in the proximal tubule. Expression of 
these enzymes was diminished in clear cell RCC along with decreased expression of VDR 
(Blomberg Jensen et al. 2010). Papillary RCC is positive for VDR in the great majority of 
cases. This recapitulates more closely the phenotype of distal tubules. Similarly, 
chromophobe carcinoma and oncocytomas are also positive for VDR. Staining of 
chromophobe carcinoma accentuates the cell membrane while in oncocytomas it is stronger 
in the perinuclear area (Liu et al. 2006). Collecting duct carcinoma is thought to derive from 
the principal cells of the collecting duct of Bellini. Consistent with other tumors of origin 
from the distal nephron, three out of three collecting duct carcinomas tested were positive 
for VDR by immunohistochemistry (Liu et al. 2006).  
Currently, immunohistochemistry for vitamin D is not routinely used for diagnostic 
purposes. However, several findings described above could eventually prove to have 
diagnostic utility in anatomic pathology. Because almost all clear cell RCC proved to be 
negative by immunohistochemistry (with the exception of some high grade tumors, or 
tumor present within vascular lumens), a positive VDR immunohistochemistry result 
should alert the pathologist about a potential problem in the classification of a tumor 
thought to be clear cell RCC (Liu et al. 2006).  
A frequent problem in the diagnosis of renal tumors is the distinction between oncocytomas 
and eosinophilic chromophobe carcinoma (Takahashi et al. 2003; Young et al. 2001). This 
distinction is critical as these tumors have completely different prognostic and therapeutic 
clinical implications. Results reported in the literature indicate that both tumors are 
immunoreactive for VDR with a difference in the localization of the stain. While 
oncocytomas stained preferably in the perinuclear area, chromophobe carcinoma showed 
accentuated stain of the cell membrane (Liu et al. 2006).  
Positive stain for VDR in papillary RCC could help differentiate this tumor from clear cell 
RCC with papillary features, which will be negative in the great majority of cases. VDR 
expression in CPRCC has not been tested; however, since these tumors are CK7 positive, it is 
likely that they are VDR positive as well, consistent with distal nephron phenotype. Only 
three cases of collecting duct carcinoma have been tested for VDR immunoreactivity and all 
of them turned positive. Differential diagnosis of these tumors could be challenging due to 
their infrequent presentations. Main differential diagnoses include adenocarcinoma or 
urothelial carcinoma with glandular differentiation. Although there is lack of information in 
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the literature regarding expression of VDR receptor in urothelial carcinoma with glandular 
differentiation, studies on normal urothelium and urothelial neoplasms have shown 
consistent positivity for VDR for which it seems unlikely that it would have utility in the 
differential diagnosis on this context (Hermann & Andersen 1997; Konety et al. 2001).  
The anti-cancer effect of vitamin D includes inhibition of cell proliferation and induction of 
apoptosis (Blutt et al. 2000; Rashid et al. 2001; Zhuang & Burnstein 1998). Expression of VDR 
as detected by immunohistochemistry was not associated with survival in a cohort of 68 
RCC patients (Obara, Konda et al. 2007). This could be due to a small number of patients 
studied or secondary to other possible alterations within the signaling pathway that could 
interfere with the normal function of the receptor. Different studies have shown consistently 
that VDR-DNA complexes are decreased in RCC, even in the presence of exogenous vitamin 
D (Madej et al. 2003; Trydal et al. 1988). This functional impairment could be secondary to 
suboptimal VDR heterodimerization with its partners in tumor cells. Before binding to 
DNA, VDR heterodimerizes with retinoid X receptor (RXR), its obligate partner (Barsony & 
Prufer 2002; Prufer & Barsony 2002). Retinoid X receptors are part of the retinoic acid 
receptor systems and share with retinoic acid part of the signaling pathways. Notably, 
positive RXR- staining in RCC correlates with prolonged overall 5-years survival (Obara, 
Konda et al. 2007).  
Calcitriol has anti-proliferative properties in a variety of malignant cell types (Getzenberg et 
al. 1997; Reichel et al. 1989). The anti-neoplastic activity of VDR ligands was first described 
in 1981 in a study showing differentiating properties of calcitriol in mouse myeloid 
leukemia cells (Abe et al. 1981). Since then, a number of studies have demonstrated the in-
vitro and in-vivo anti-cancer potential of vitamin D in models of bladder, breast, colon, 
endometrium, lung, pancreas, prostate and squamous cell carcinoma, sarcomas of the soft 
tissues and bone, neuroblastoma, glioma, melanoma, and other malignancies (Beer & 
Myrthue 2004; Trump et al. 2004; Trump et al. 2006).  
Calcitriol treatment of cells inhibited cell growth and clonogenicity of the RCC cell line 
derived from a pulmonary metastasis of RCC, (Nagakura et al. 1986). In a different study, 
BALB/c mice were inoculated with murine renal cancer Renca and graded doses of calcitriol 
were given intraperitoneally. Vitamin D inhibited tumor growth and prolonged the life span 
of Renca-bearing mice in a dose-dependent manner. Furthermore, vitamin D treated mice 
showed reduced pulmonary and hepatic metastates (Fujioka et al. 1998). Despite these and 
other promising results in cell culture and in murine models, the utility of vitamin D 
therapy in humans has been challenged by its hypercalcemic toxic effect (Fakih et al. 2007; 
Muindi et al. 2009). To try to bypass this toxicity, researchers have explored alternative 
vitamin D like molecules. A recent published study investigated the in-vitro and in-vivo 
effect of 1,25-dihydroxyvitamin D3-3-bromoacetate [1,25(OH)2D3-3-BE], an alkylating 
derivative of 1,25(OH)2D3 (Lambert et al. 2010). This study reports that 1,25(OH)2D3-3-BE is 
significantly more potent than an equivalent concentration of 1,25(OH)2D3 in inhibiting 
growth of A498 and Caki 1 human kidney cancer cells. The mechanisms behind cell growth 
inhibition of cell-cycle progression include downregulating cyclin A and induction of 
apoptosis through caspase activity. When compared to calcitriol, 1,25(OH)2D3-3-BE was 
more potent at reducing tumor size, which was accompanied by an increase in apoptosis 
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and reduction of cyclin A staining in the tumors. These results show a promising potential 
of vitamin D derived compounds as targeted therapy for RCC patients (Lambert et al. 2010).  
8. Retinoic acid receptors 
Retinoids are a family of molecules related to vitamin A that include retinoic acid (RA) and 
all-trans retinoid. Retinoids participate in diverse functions in many organ systems during 
development and in adulthood including vision, neural function and immune response. 
Extensive research also supports a role of retinoids in cell proliferation and differentiation 
through cell cycle signaling promoting block in G1 phase of cell cycle, by directly or 
indirectly modulating cyclins, CDKs, and cell-cycle inhibitors (Mongan & Gudas 2007; Tang 
& Gudas 2011). There are two distinct retinoid nuclear receptor systems, the RARs types -, 
- and -, and RXRs types -, - and - (Pemrick et al. 1994). RARs form heterodimers with 
RXRs and act by binding to retinoic acid response elements (RARE) located in the promoter 
regions of RA-target genes and modulate transcription rates (Altucci & Gronemeyer 2001). 
In addition to its role in senescence and cell differentiation, retinoic acid can follow an 
alternative pathway by binding to a so-called orphan nuclear receptor, PPAR-/- to 
promote cell survival under certain conditions (Schug et al. 2007).  
8.1 Expression of retinoic acid receptors in the normal kidney 
Studies evaluating the expression of RARs and RXRs indicate that expression of a given 
receptor subtype is cell type specific and that retinoic acid effect in different cell types are 
linked to specific receptor type (Geradts et al. 1993; Kakizuka et al. 1991; Moasser et al. 1994; 
Moasser et al. 1995; Sheikh et al. 1994; Swisshelm et al. 1994). Information on expression of 
RARs in normal kidney derives primarily from normal controls used in studies for various 
purposes. RAR- mRNA has consistently been found to be expressed in normal kidney 
tissue samples (Goelden et al. 2005; Vanderleede et al. 1995). Additionally, expression of 
RARs and RXRs were studied in podocytes, which expressed most isoforms of retinoic acid 
receptors (RAR) and RXRs with the exception of RXR- (He et al. 2007). Obara et al. detected 
expression of RXR- and- in nuclei of proximal tubule cells, while RXR- expression was 
present in proximal tubule cells and interstitial cells (Obara, Konda et al. 2007).  
8.2 Expression of retinoic acid receptors in kidney tumors 
Dysregulation of each RA receptor has been found in association with different types of 
cancer. RAR- is dysregulated in acute promyelocytic leukemia (APL). Majority of APL 
cases present a chromosomal translocation that fuses the promyelocytic leukemia gene, PML 
and the RAR- genes [t(15;17)(22;q11.2-12)] which can be effectively treated and cured with 
a combination of retinoid and chemotherapy. In contrast to RAR-, RAR- is involved in 
solid tumorigenesis including RCC (Argiles et al. 1994; Berg et al. 1999; Goelden et al. 2005; 
Hoffman et al. 1996). The RAR- gene maps on the short arm of chromosome 3, a region 
frequently deleted in cancer (Houle et al. 1993). Several studies demonstrated decreased or 
undetectable levels of RAR- mRNA in tissue or cell lines derived from different tumors 
including lung (Suh et al. 2002; Zhang et al. 1994), prostate (Nakayama et al. 2001), breast 
(Swisshelm et al. 1994), ovary (Sabichi et al. 1998), colon (Cote et al. 1998), head and neck 
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(Xu et al. 1994) and cervix (Geisen et al. 1997). RAR- mRNA was decreased or not 
detectable in 11 of 12 RCC cell lines (Hoffman et al. 1996). These cell lines were either 
resistant or minimally inhibited when treated with 13-cis-RA (13-CRA). Conversely, 
chromophobe RCC shows much higher levels of expression of RAR- with a ratio of 
tumor/normal of over 36 (Goelden et al. 2005). In clear cell RCC, immunoreactivity for RXR-
 was observed in up to 70% of the cases, RXR- was present in 47% of cases, and RXR- 
stain was seen in 85% of cases, in a study that included 49 CRCCs (Obara, Konda et al. 2007). 
Only expression of RXR- was found to correlate inversely with pathological and clinical 
stage. While all subtypes of RXRs showed variable nuclear or cytoplasmic stain, subcellular 
location did not correlate with any prognostic variables. Additionally, this study suggests a 
prolonged overall 5-year survival of patients with tumors that are RXR- positive (Obara, 
Konda et al. 2007).  
In clinical trials, the effect of RA in RCC patients has been tested in patients with metastatic 
disease. A randomized clinical trial of 284 patients evaluated response to treatment with 
IFN2a plus 13-cis-retinoic acid (13-CRA) or treatment with IFN2a alone (Motzer et al. 
2000). This study showed no difference in the overall survival but median duration of 
response (complete and partial combined) in the group treated with the combination was 33 
months versus 22 months for the second group. Nineteen percent of patients treated with 
IFN2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients 
treated with IFN2a alone (Motzer et al. 2000). However, a separate clinical trial that 
involved 320 patients concluded that progression-free and overall survival for patients with 
progressive metastatic RCC treated with IFN2a plus 13-CRA were significantly longer 
compared with patients on IFN alone (Aass et al. 2005). Another clinical trial that included 
three different treatment regimens: a) triple combination of IL-2, IFN2a, and fluorouracil; b) 
triple combination of group a and additional 13-CRA; c) control group treated with IFN- 
and vinblastine. Progression-free and overall survival were significantly longer in groups a 
and b but there was no significant survival advantage for patients receiving 13-CRA 
(Atzpodien et al. 2004). These studies suggest that there is some beneficial effect of retinoids 
treatment, in at least a subset of patients with RCC. 
9. Conclusion 
Steroid receptors are differentially expressed in the normal kidney and in renal cell 
neoplasms. Several steroid receptors, such as MR, PR, and vitamin D receptor may be 
included in diagnostic immunohistochemical panels in order to more accurately subtype 
renal cell tumors. Although ER is not detected in significant amounts in RCCs, it is 
expressed by stromal cells in several benign renal neoplasms and may be involved in their 
pathogenesis. GR and AR appear to be markers of less aggressive behavior in clear cell RCC. 
Finally, steroid receptors and their downstream signaling mechanisms may have a potential 
role in novel anticancer hormonal therapies in RCCs. 
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